BiotechTube

E6007 + Placebo

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Moderate Active Ulcerative Colitis

Conditions

Moderate Active Ulcerative Colitis

Trial Timeline

Nov 28, 2016 → Aug 16, 2019

NCT ID
NCT03018054

About E6007 + Placebo

E6007 + Placebo is a phase 2 stage product being developed by Eisai for Moderate Active Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03018054. Target conditions include Moderate Active Ulcerative Colitis.

What happened to similar drugs?

18 of 20 similar drugs in Moderate Active Ulcerative Colitis were approved

Approved (18) Terminated (4) Active (2)
✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
✅tacrolimusAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
✅Risankizumab + DeucravacitinibAbbVieApproved
✅adalimumabAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03018054Phase 2Completed

Competing Products

20 competing products in Moderate Active Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved
44
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
44
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
44
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
47
PexidartinibDaiichi SankyoPhase 1
29
CS-3150Daiichi SankyoPhase 3
40
tacrolimusAstellas PharmaApproved
43
AlefaceptAstellas PharmaApproved
43
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
Tildrakizumab 100 mg + PlaceboSun PharmaceuticalPhase 3
44
Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + PlaceboSun PharmaceuticalPhase 2/3
42
Ranirestat + PlaceboEisaiPhase 2/3
38
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827 + PlaceboKyowa KirinPhase 3
40
KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved
35
KHK4827 + PlaceboKyowa KirinPhase 2
35
Stelara + Bmab1200BioconPhase 3
40
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringeBioconPhase 3
40